Business · 1 sources covering this

Expanding innovative portfolio may drive gains for Sun Pharma stock

Lerodalcibep licensing deal, growth in the US portfolio and tariff relief offer triggers, while the proposed Organon acquisition could broaden its global reach

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

Business StandardCenter·1h ago
Expanding innovative portfolio may drive gains for Sun Pharma stock
Lerodalcibep licensing deal, growth in the US portfolio and tariff relief offer triggers, while the proposed Organon acquisition could broaden its global reach
Read at Business Standard →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/6a90ad8cf60e7c977dfe0c69f9f5bf76b7b59ccd"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Expanding innovative portfolio may drive gains for Sun Pharma stock"></iframe>

Expanding innovative portfolio may drive gains for Sun Pharma stock

How 1 sources are covering this

Expanding innovative portfolio may drive gains for Sun Pharma stock

More from Business

Nomura projects terminal repo rate of 5.75% following Oct, Dec hikes

CAG flags ₹1,662 cr DMF spend outside norms, mining-affected areas

Monika Shergill confirms Lock Upp return

TVS Motor leases 529,533 sq ft office space in Bengaluru for 10 years

Reader

Trust & legal

Across the network